Navigation Links
European Society for Medical Oncology and European CanCer Organization join forces
Date:4/9/2008

Lugano, Switzerland and Brussels, Belgium, 9 April 2008: The European Society for Medical Oncology (ESMO) and ECCO - the European CanCer Organisation have united forces to host a co-branded biennial multidisciplinary partnership meeting that will provide the best and most updated scientific data for everyone working in cancer and will also strengthen initiatives aimed at providing all cancer patients with equal access to high-quality cancer care.

The ECCO Congress, which takes place every two years, will become a joint ECCO-ESMO congress, and its scientific committee will be chaired both by ECCO and ESMO. The first congress will be 20-24 September 2009 in Berlin, with subsequent joint congresses being held biennially in the uneven-numbered years.

In the intervening even-numbered years between the ECCO-ESMO congresses, ESMO will continue to hold its own ESMO Congress. In 2008, the 33rd ESMO Congress will take place as planned, 12-16 September, in Stockholm, Sweden.

In addition, ESMOs Board of Directors unanimously voted on 4 April to become a founding member of the new ECCO organisation, composed of European cancer societies, and as a result, ESMO will have a seat on the ECCO Board of Directors. The ECCO Board unanimously accepted the proposal two weeks ago.

ECCO President, Professor Alexander M.M. Eggermont, said he was delighted. ESMO and ECCO have been discussing this for some time now, and we firmly believe that joining forces in this way will benefit all our member organisations, European cancer professionals and, most importantly, cancer patients.

With so much happening in Europe affecting advances in oncology, we need to work together when interacting with European policymakers and industry, so that they take notice, understand and act on our messages. ECCOs mission is to uphold the right of all cancer patients to the best possible treatment and care and to promote interaction between all organisations involved in cancer research, education, treatment and care at the European level. Together with ESMO, I am confident that we will be able to achieve this goal.

ESMO President, Professor Jos Baselga agreed, and added: This uniting of the landscape of European oncology is the result of an agreement on common goals combined with a strong spirit of goodwill and collaboration on all sides. In becoming a founding member of ECCO, we are convinced we will strengthen our ability to represent European oncologists and patients. ESMO is a community of professionals who share the common goal of providing the best possible care for all cancer patients a mission which is in total harmony with ECCOs objectives.

This is a win-win situation for ESMO, ECCO and all of our patients. I am looking forward to liaising closely with Professor Eggermont, not only in supporting medical oncology and cancer treatment by multidisciplinary teams, but also in working towards enhancing European conferences as attractive settings to present research done in Europe and worldwide. Looking ahead, we will combine our efforts to make the 2009 ECCO 15 34th ESMO Congress the best and biggest European cancer congress yet.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
07-711-296-986
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
2. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
3. IOF recognizes ESCEO European guidance for osteoporosis diagnosis and management
4. More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
5. Gene expression differences between Europeans and Africans affect response to drugs, infections
6. Space sentinels: New tools in space to improve European environment and security policies
7. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
8. Specialty European Pharma launches plenaxis in Germany
9. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
10. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
11. European Neuroscience and Society Network tackles neurosocieties head-on
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... York, NY (PRWEB) , ... May 25, 2016 ... ... Medicine and Florida International University (FIU) Herbert Wertheim College of Medicine announced the ... a Medical Doctor Degree and Global Health Certificate from AUA and a Certificate ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Dr. Travis Schwarz ... Plaza at 8618 Mexico Road, O’Fallon, MO 63366. He serves patients of all ages ... cosmetic treatments . Dr. Schwarz’s success is reflected in the superior patient reviews that ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Today Omega ... launch of 11 innovative workshops and training opportunities in the growing field ... unique needs of individuals who are dealing with specific health issues—including injuries, illnesses, and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Cheryl Bowker of Bowker Insurance Group ... Dick McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s most successful agencies ... inspire all those who knew him. The award named for him is not given ...
(Date:5/25/2016)... ... 2016 , ... The Global Wellness Summit (GWS) today announced that its 2016 ... Europe, a continent that pioneered the medical/wellness concept for the world. , Delegates to ... wellness, including Henri Chenot, Founder of the Chenot Group, which operates wellness centers around ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... N.J. , May 24, 2016 ... oncology drug development company, today provided an update ... dose escalating clinical trial combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  GEN-1 is an IL-12 DNA ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology: